Clear Creek Bio is a private, clinical-stage biotech company focused on developing novel therapies to address infectious disease and cancer. The company’s lead drug candidate, brequinar, is a dihydroorotate dehydrogenase (DHODH) inhibitor with oral bioavailability and high potency. Clear Creek Bio is evaluating brequinar in clinical trials as a potential once-daily treatment for COVID-19. The company is also assessing brequinar as a potential treatment for acute myeloid leukemia.